Trials / Completed
CompletedNCT00504881
Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy
An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (≥ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 480 (actual)
- Sponsor
- UCB Pharma SA · Industry
- Sex
- All
- Age
- 16 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will compare the safety and efficacy of Brivaracetam at flexible dose with Placebo in subjects suffering from Epilepsy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 16-week Treatment Period |
| DRUG | Brivaracetam | Daily oral dose of two equal intakes, morning and evening, Brivaracetam 20 mg/day or Brivaracetam 50 mg/day or Brivaracetam 100 mg/day or Brivaracetam 150 mg/day, in a double-blinded way for the 16-week Treatment Period |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2008-11-01
- Completion
- 2008-12-01
- First posted
- 2007-07-20
- Last updated
- 2018-04-03
- Results posted
- 2017-03-17
Locations
61 sites across 15 countries: Austria, Belgium, Czechia, Germany, Hong Kong, India, Italy, Norway, Russia, Singapore, South Africa, South Korea, Sweden, Taiwan, Ukraine
Source: ClinicalTrials.gov record NCT00504881. Inclusion in this directory is not an endorsement.